---
title: "Abbisko Advances FGFR4 Inhibitor Irpagratinib With First U.S. Patient Dosed in Global HCC Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275528457.md"
description: "Abbisko Cayman Limited has dosed the first U.S. patient in a global Phase I trial of irpagratinib, an FGFR4 inhibitor for advanced hepatocellular carcinoma. The drug has received Fast Track designation from the U.S. FDA and Breakthrough Therapy designation in China. Early data show durable antitumor activity and a favorable safety profile. Abbisko aims to accelerate global development and commercialization of irpagratinib, which shows promise in first-line HCC treatment. The current analyst rating for Abbisko stock (HK:2256) is a Hold with a price target of HK$13.00."
datetime: "2026-02-11T00:12:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275528457.md)
  - [en](https://longbridge.com/en/news/275528457.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275528457.md)
---

# Abbisko Advances FGFR4 Inhibitor Irpagratinib With First U.S. Patient Dosed in Global HCC Trial

### Valentine's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Abbisko Cayman Limited ( (HK:2256) ) has provided an update.

Abbisko Therapeutics has dosed the first U.S. patient in the expansion phase of a global Phase I trial of irpagratinib, its highly selective oral FGFR4 inhibitor for patients with FGF19-overexpressing advanced hepatocellular carcinoma. The drug has received both Fast Track designation from the U.S. FDA and Breakthrough Therapy designation in China, reflecting regulators’ recognition of its potential to address a high unmet need.

Early data from the China cohort show durable antitumor activity and a favorable safety profile, with particularly strong responses in patients previously treated with immune checkpoint and multi-targeted kinase inhibitors. Combination Phase II data with atezolizumab also indicate robust efficacy and manageable safety, positioning irpagratinib as a promising candidate in first-line HCC treatment and underscoring Abbisko’s push to accelerate global development and commercialization.

The most recent analyst rating on (HK:2256) stock is a Hold with a HK$13.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

**More about Abbisko Cayman Limited**

Abbisko Cayman Limited is a clinical-stage biopharmaceutical group focused on developing small-molecule targeted therapies, primarily through its subsidiary Abbisko Therapeutics. The company is concentrating on precision oncology, with a particular emphasis on advanced hepatocellular carcinoma and other solid tumors driven by specific molecular alterations.

**Average Trading Volume:** 1,832,094

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$8.6B

Learn more about 2256 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [02256.HK](https://longbridge.com/en/quote/02256.HK.md)

## Related News & Research

- [Abbisko Moves to Modernise Governance With Digital-Ready Articles Update](https://longbridge.com/en/news/284382620.md)
- [Abbisko Advances KRAS G12D Cancer Program With First Patient Dosed in ABSK141 Trial](https://longbridge.com/en/news/277696391.md)
- [TransThera reports promising tinengotinib results in advanced solid tumors](https://longbridge.com/en/news/286670762.md)
- [Sino Biopharm says China approves zongertinib for first-line HER2-mutant NSCLC](https://longbridge.com/en/news/287221446.md)
- [20:00 ETAccro Bioscience Announces $50 Million Series C Financing Led by OrbiMed to Advance Clinical Pipeline for Immune Mediated Diseases](https://longbridge.com/en/news/286830151.md)